Literature DB >> 21635931

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder.

Courtney S Jernigan1, Dharmendra B Goswami, Mark C Austin, Abiye H Iyo, Agata Chandran, Craig A Stockmeier, Beata Karolewicz.   

Abstract

Recent studies demonstrate that rapid antidepressant response to ketamine is mediated by activation of the mammalian target of rapamycin (mTOR) signaling pathway, leading to increased synaptic proteins in the prefrontal cortex (PFC) of rats. Our postmortem studies indicate robust deficits in prominent postsynaptic proteins including N-methyl-d-aspartate (NMDA) receptor subunits (NR2A, NR2B), metabotropic glutamate receptor subtype 5 (mGluR5) and postsynaptic density protein 95kDa (PSD-95) in the PFC in major depressive disorder (MDD). We hypothesize that deficits in the mTOR-dependent translation initiation pathway contribute to the molecular pathology seen in the PFC of MDD subjects, and that a rapid reversal of these abnormalities may underlie antidepressant activity. The majority of known translational regulation occurs at the level of initiation. mTOR regulates translation initiation via its downstream components: p70-kDa ribosomal protein S6 kinase (p70S6K), and eukaryotic initiation factors 4E and 4B (eIF4E and eIF4B). In this study, we examined the expression of mTOR and its core downstream signaling targets: p70S6K, eIF4E, and eIF4B in the PFC of 12 depressed subjects and 12 psychiatrically healthy controls using Western blot. Levels of eIF4E phosphorylated at serine 209 (p-eIF4E-Ser209) and eIF4B phosphorylated at serine 504 (p-eIF4B-Ser504) were also examined. Adjacent cortical tissue samples from both cohorts of subjects were used in our previous postmortem analyses. There was a significant reduction in mTOR, p70S6K, eIF4B and p-eIF4B protein expression in MDD subjects relative to controls. No group differences were observed in eIF4E, p-eIF4E or actin levels. Our findings show deficits in mTOR-dependent translation initiation in MDD particularly via the p70S6K/eIF4B pathway, and indicate a potential association between marked deficits in synaptic proteins and dysregulation of mTOR signaling in MDD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635931      PMCID: PMC3154612          DOI: 10.1016/j.pnpbp.2011.05.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  27 in total

Review 1.  eIF4A: the godfather of the DEAD box helicases.

Authors:  George W Rogers; Anton A Komar; William C Merrick
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2002

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

3.  The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex.

Authors:  Se Chang Yoon; Myoung Suk Seo; Se Hyun Kim; Won Je Jeon; Yong Min Ahn; Ung Gu Kang; Yong Sik Kim
Journal:  Neurosci Lett       Date:  2008-01-16       Impact factor: 3.046

4.  A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus.

Authors:  Shao Jun Tang; Gerald Reis; Hyejin Kang; Anne-Claude Gingras; Nahum Sonenberg; Erin M Schuman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

5.  Chronic fluoxetine induces region-specific changes in translation factor eIF4E and eEF2 activity in the rat brain.

Authors:  Grethe Dagestad; Sjoukje D Kuipers; Elhoucine Messaoudi; Clive R Bramham
Journal:  Eur J Neurosci       Date:  2006-05       Impact factor: 3.386

6.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

Review 7.  Nosology of chronic mood disorders.

Authors:  M B First; S Donovan; A Frances
Journal:  Psychiatr Clin North Am       Date:  1996-03

8.  Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine.

Authors:  Kenji Hashimoto
Journal:  Expert Rev Neurother       Date:  2011-01       Impact factor: 4.618

9.  Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction.

Authors:  Zhong Zhao; Hanna Ksiezak-Reding; Silvana Riggio; Vahram Haroutunian; Giulio M Pasinetti
Journal:  Schizophr Res       Date:  2006-04-11       Impact factor: 4.939

10.  Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.

Authors:  Anteneh M Feyissa; William L Woolverton; Jose J Miguel-Hidalgo; Zhixia Wang; Patrick B Kyle; Gregor Hasler; Craig A Stockmeier; Abiye H Iyo; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-11-26       Impact factor: 5.067

View more
  135 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

2.  Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels.

Authors:  Lauren Osborne; Makena Clive; Mary Kimmel; Fiona Gispen; Jerry Guintivano; Tori Brown; Olivia Cox; Jennifer Judy; Samantha Meilman; Aviva Braier; Matthias W Beckmann; Johannes Kornhuber; Peter A Fasching; Fernando Goes; Jennifer L Payne; Elisabeth B Binder; Zachary Kaminsky
Journal:  Neuropsychopharmacology       Date:  2015-10-27       Impact factor: 7.853

Review 3.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Authors:  Kathy Sengmany; Junaid Singh; Gregory D Stewart; P Jeffrey Conn; Arthur Christopoulos; Karen J Gregory
Journal:  Neuropharmacology       Date:  2016-07-05       Impact factor: 5.250

5.  GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.

Authors:  Rong-Jian Liu; Catharine Duman; Taro Kato; Brendan Hare; Dora Lopresto; Eunyoung Bang; Jeffery Burgdorf; Joseph Moskal; Jane Taylor; George Aghajanian; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2016-09-16       Impact factor: 7.853

6.  Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway.

Authors:  Jing-Jie Yu; Yong Zhang; Ying Wang; Zi-Yu Wen; Xiao-Hua Liu; Jing Qin; Jian-Li Yang
Journal:  Psychopharmacology (Berl)       Date:  2012-08-09       Impact factor: 4.530

7.  Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice.

Authors:  Lu Song; Hao Wang; Ying-Jie Wang; Jin-Liang Wang; Qing Zhu; Feng Wu; Wei Zhang; Bo Jiang
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

8.  Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior.

Authors:  Jason M Dwyer; Jaime G Maldonado-Avilés; Ashley E Lepack; Ralph J DiLeone; Ronald S Duman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

9.  Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats.

Authors:  Ambalika Sarkar; Mohamed Kabbaj
Journal:  Biol Psychiatry       Date:  2016-01-11       Impact factor: 13.382

Review 10.  New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.

Authors:  Zuleide M Ignácio; Gislaine Z Réus; Camila O Arent; Helena M Abelaira; Meagan R Pitcher; João Quevedo
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.